BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maduro JH, Noordhuis MG, ten Hoor KA, Pras E, Arts HJ, Eijsink JJ, Hollema H, Mom CH, de Jong S, de Vries EG, de Bock GH, van der Zee AG. The Prognostic Value of TRAIL and its Death Receptors in Cervical Cancer. International Journal of Radiation Oncology*Biology*Physics 2009;75:203-11. [DOI: 10.1016/j.ijrobp.2009.03.071] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Heilmann T, Vondung F, Borzikowsky C, Szymczak S, Krüger S, Alkatout I, Wenners A, Bauer M, Klapper W, Röcken C, Maass N, von Karstedt S, Schem C, Trauzold A. Heterogeneous intracellular TRAIL-receptor distribution predicts poor outcome in breast cancer patients. J Mol Med (Berl) 2019;97:1155-67. [PMID: 31183506 DOI: 10.1007/s00109-019-01805-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
2 Shafabakhsh R, Reiter RJ, Mirzaei H, Teymoordash SN, Asemi Z. Melatonin: A new inhibitor agent for cervical cancer treatment. J Cell Physiol 2019;234:21670-82. [PMID: 31131897 DOI: 10.1002/jcp.28865] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
3 Chen L, Luan S, Xia B, Liu Y, Gao Y, Yu H, Mu Q, Zhang P, Zhang W, Zhang S, Wei G, Yang M, Li K. Integrated analysis of HPV-mediated immune alterations in cervical cancer. Gynecol Oncol 2018;149:248-55. [PMID: 29572030 DOI: 10.1016/j.ygyno.2018.01.031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
4 Wang W, Li J, Wen Q, Luo J, Chu S, Chen L, Qing Z, Xie G, Xu L, Alnemah MM, Li M, Fan S, Zhang H. 4EGI-1 induces apoptosis and enhances radiotherapy sensitivity in nasopharyngeal carcinoma cells via DR5 induction on 4E-BP1 dephosphorylation. Oncotarget 2016;7:21728-41. [PMID: 26942880 DOI: 10.18632/oncotarget.7824] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
5 Shehzad A, Parveen S, Qureshi M, Subhan F, Lee YS. Decursin and decursinol angelate: molecular mechanism and therapeutic potential in inflammatory diseases. Inflamm Res 2018;67:209-18. [PMID: 29134229 DOI: 10.1007/s00011-017-1114-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
6 Komdeur FL, Prins TM, van de Wall S, Plat A, Wisman GBA, Hollema H, Daemen T, Church DN, de Bruyn M, Nijman HW. CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. Oncoimmunology 2017;6:e1338230. [PMID: 28932636 DOI: 10.1080/2162402X.2017.1338230] [Cited by in Crossref: 85] [Cited by in F6Publishing: 78] [Article Influence: 17.0] [Reference Citation Analysis]
7 Naoum GE, Buchsbaum DJ, Tawadros F, Farooqi A, Arafat WO. Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology. Oncol Rev 2017;11:332. [PMID: 28584572 DOI: 10.4081/oncol.2017.332] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
8 Oh YT, Yue P, Wang D, Tong JS, Chen ZG, Khuri FR, Sun SY. Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling. Oncotarget 2015;6:41324-38. [PMID: 26510914 DOI: 10.18632/oncotarget.5847] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
9 Fritsche H, Heilmann T, Tower RJ, Hauser C, von Au A, El-Sheikh D, Campbell GM, Alp G, Schewe D, Hübner S, Tiwari S, Kownatzki D, Boretius S, Adam D, Jonat W, Becker T, Glüer CC, Zöller M, Kalthoff H, Schem C, Trauzold A. TRAIL-R2 promotes skeletal metastasis in a breast cancer xenograft mouse model. Oncotarget 2015;6:9502-16. [PMID: 25909161 DOI: 10.18632/oncotarget.3321] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
10 Lin MT, Lin CL, Lin TY, Cheng CW, Yang SF, Lin CL, Wu CC, Hsieh YH, Tsai JP. Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway. Tumour Biol 2016;37:6987-96. [PMID: 26662956 DOI: 10.1007/s13277-015-4526-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
11 Yao Q, Du J, Lin J, Luo Y, Wang Y, Liu Y, Zhang B, Ren C, Liu C. Prognostic significance of TRAIL signalling molecules in cervical squamous cell carcinoma. J Clin Pathol 2016;69:122-7. [PMID: 26254281 DOI: 10.1136/jclinpath-2014-202811] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
12 Manzo-merino J, Contreras-paredes A, Vázquez-ulloa E, Rocha-zavaleta L, Fuentes-gonzalez AM, Lizano M. The Role of Signaling Pathways in Cervical Cancer and Molecular Therapeutic Targets. Archives of Medical Research 2014;45:525-39. [DOI: 10.1016/j.arcmed.2014.10.008] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 7.0] [Reference Citation Analysis]
13 Bertsch U, Röder C, Kalthoff H, Trauzold A. Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2. Cell Death Dis 2014;5:e1390. [PMID: 25165876 DOI: 10.1038/cddis.2014.351] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
14 Hernandez-Cueto A, Hernandez-Cueto D, Antonio-Andres G, Mendoza-Marin M, Jimenez-Gutierrez C, Sandoval-Mejia AL, Mora-Campos R, Gonzalez-Bonilla C, Vega MI, Bonavida B, Huerta-Yepez S. Death receptor 5 expression is inversely correlated with prostate cancer progression. Mol Med Rep 2014;10:2279-86. [PMID: 25174820 DOI: 10.3892/mmr.2014.2504] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
15 Wang XG, Jandl T, Dadachova E, Revskaya E. Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in mice. Ther Deliv 2014;5:139-47. [PMID: 24483193 DOI: 10.4155/tde.13.137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
16 Krieg A, Mersch S, Wolf N, Stoecklein NH, Verde PE, am Esch JS 2nd, Heikaus S, Gabbert HE, Knoefel WT, Mahotka C. Expression of TRAIL-splice variants in gastric carcinomas: identification of TRAIL-γ as a prognostic marker. BMC Cancer 2013;13:384. [PMID: 23937794 DOI: 10.1186/1471-2407-13-384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
17 Roossink F, Wieringa HW, Noordhuis MG, ten Hoor KA, Kok M, Slagter-Menkema L, Hollema H, de Bock GH, Pras E, de Vries EG, de Jong S, van der Zee AG, Schuuring E, Wisman GB, van Vugt MA. The role of ATM and 53BP1 as predictive markers in cervical cancer. Int J Cancer 2012;131:2056-66. [PMID: 22323184 DOI: 10.1002/ijc.27488] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
18 Jo M, Park MH, Kollipara PS, An BJ, Song HS, Han SB, Kim JH, Song MJ, Hong JT. Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2/STAT3 pathway. Toxicol Appl Pharmacol 2012;258:72-81. [PMID: 22027265 DOI: 10.1016/j.taap.2011.10.009] [Cited by in Crossref: 153] [Cited by in F6Publishing: 157] [Article Influence: 13.9] [Reference Citation Analysis]
19 Niu Y, Li Y, Zang J, Huang H, Deng J, Cui Z, Yu D, Deng J. Death Receptor 5 and Neuroproliferation. Cell Mol Neurobiol 2012;32:255-65. [DOI: 10.1007/s10571-011-9757-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
20 Noordhuis MG, Eijsink JJ, Roossink F, de Graeff P, Pras E, Schuuring E, Wisman GB, de Bock GH, van der Zee AG. Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review. Int J Radiat Oncol Biol Phys 2011;79:325-34. [PMID: 21195874 DOI: 10.1016/j.ijrobp.2010.09.043] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 5.1] [Reference Citation Analysis]
21 Elrod HA, Fan S, Muller S, Chen GZ, Pan L, Tighiouart M, Shin DM, Khuri FR, Sun SY. Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact. PLoS One 2010;5:e12178. [PMID: 20808443 DOI: 10.1371/journal.pone.0012178] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
22 Mahmood Z, Shukla Y. Death receptors: Targets for cancer therapy. Experimental Cell Research 2010;316:887-99. [DOI: 10.1016/j.yexcr.2009.12.011] [Cited by in Crossref: 132] [Cited by in F6Publishing: 135] [Article Influence: 11.0] [Reference Citation Analysis]